Johnson & Johnson Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Johnson & Johnson (NYSE:JNJ)

Core Viewpoint - Johnson & Johnson is set to report its fourth-quarter earnings on January 21, with expectations of increased earnings per share and revenue compared to the previous year [1] Financial Performance - Analysts predict fourth-quarter earnings of $2.47 per share, up from $2.04 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $24.16 billion, an increase from $22.52 billion reported last year [1] Recent Developments - On January 14, Johnson & Johnson announced topline results from the Phase 3 MajesTEC-9 study of Tecvayli for multiple myeloma, which may impact investor sentiment [2] - Following the announcement, shares of Johnson & Johnson fell by 0.2% to close at $218.21 [2] Analyst Ratings - Bernstein analyst Lee Hambright maintained a Market Perform rating and raised the price target from $193 to $208 [4] - Barclays analyst Matt Miksic maintained an Equal-Weight rating and increased the price target from $197 to $217 [4] - Goldman Sachs analyst Asad Haider maintained a Buy rating and raised the price target from $213 to $240 [4] - B of A Securities analyst Tim Anderson maintained a Neutral rating and increased the price target from $204 to $220 [4] - Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and raised the price target from $190 to $197 [4]